Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
PainChek Ltd ( (AU:PCK) ) just unveiled an announcement.
PainChek Ltd has announced the expiry of 6,354,951 unexercised options with an exercise price of $0.50, which ceased on 24 March 2026. The lapse of these options, disclosed via an Appendix 3H notification, reduces the pool of potential dilutive securities on issue and slightly simplifies the company’s capital structure, with no immediate cash inflow from option conversion for the company.
The cessation of these options may marginally affect future dilution expectations for existing shareholders, but does not alter the number of ordinary shares currently on issue. This routine capital management event signals the end of a specific series of incentive or investment options and provides updated transparency to the market on PainChek’s outstanding securities profile.
The most recent analyst rating on (AU:PCK) stock is a Hold with a A$0.14 price target. To see the full list of analyst forecasts on PainChek Ltd stock, see the AU:PCK Stock Forecast page.
More about PainChek Ltd
PainChek Ltd is an ASX-listed company in the healthcare technology sector, trading under the ticker PCK. The company develops and commercialises digital tools, including software-based solutions, to assess and monitor pain, targeting clinical and aged-care settings where objective pain measurement is critical.
Average Trading Volume: 157,496
Technical Sentiment Signal: Sell
Current Market Cap: A$29.26M
For an in-depth examination of PCK stock, go to TipRanks’ Overview page.